

BIOXIS Pharmaceuticals Labelled Innovative Company of the French Clusters, Enterprise Innovante des Poles (EIP)

Paris, France – June 2015: After 6 months of mentoring, BIOXIS has been awarded the highly prestigious label EIP (Enterprise Innovante des Poles) by Medicen General Delegate, Mrs. Beatrice Falise-Mirat.

This label helps innovative, high potential companies like BIOXIS to attract private investors. By leveraging private financing, the label helps increase the company's visibility and encourages, "business angels" and investment funds to discover promising startup in the French eco-system.

During the Paris-held ceremony, CEO and founder, Frederic Bertaina declared, "this label will certainly help BIOXIS to quickly finalize negotiations with investors who are highly enthused by our technology and its various healthcare applications."

About EIP Label

This label of excellence was launched by the French Ministry of Economy to identify companies with strong technological and market capabilities.

For more information, visit

www.competitivite.gouv.fr/financement-prive/le-label-entreprises-innovantes-des-poles-763.html

About Medicen Paris Region

Medicen Paris Region is one of Europe's largest clusters in Life Sciences and Healthcare, and a gateway to European biotechnology markets. With more than 200 members, its goal is to increase the attractiveness of the Paris region, to strengthen the international competitiveness of the health sector, and to develop its members' economic growth in strategic markets through collaborative innovation.

For more information, visit www.medicen.org

About BIOXIS Pharmaceuticals

Bioxis specializes in the discovery, development, production, and commercialization of innovative regenerative medicine products. Through groundbreaking solutions, the company develops popular products that help doctors improve quality of care.

For more information, visit www.bioxis.com

